细胞和基因治疗生物製造 CDMO 市场：按组成部分、阶段和适应症分类 - 全球预测 2025-2030

2023年细胞和基因治疗生物製造CDMO市场价值为3.3812亿美元，预计2024年将达到4.8547亿美元，复合年增长率为32.53%，2030年将达到2.4%，预计将达到2890万亿美元。

细胞和基因治疗生物製造合约开发和受託製造厂商(CDMO) 是生物製药行业的重要组成部分，专注于针对遗传疾病和癌症的高度个人化治疗的客製化生产。此细分市场的推动因素包括慢性病的日益普及、CRISPR 等基因编辑技术的进步以及生物技术研发投资的增加。对 CDMO 的需求源于细胞和基因疗法生产的复杂性和资源集中性质，这需要专门的设施、技术专长并遵守严格的监管标准。这些治疗方法的应用多种多样，包括癌症治疗、罕见遗传疾病和再生医学，最终用途主要是医院、研究机构和生物技术公司。主要成长动力包括细胞和基因疗法监管核准率的提高、製造流程的技术进步以及公共和私人资金的增加。潜在的商机包括扩大与生物技术公司的伙伴关係，透过自动化和人工智慧提高製造能力，以及扩大生产规模以满足不断增长的需求。为企业提供的研究提案包括投资最先进的设备、培养技术纯熟劳工以及与研究机构合作持续创新。然而，市场扩张受到高製造成本、治疗交付中的物流挑战以及监管障碍的限制。此外，治疗药物的高成本限制了患者立即获得治疗，而对基因改造的伦理担忧可能会延迟更广泛的接受。需要创新的领域包括制定具有成本效益的生产策略、改善供应链物流以及发现新的治疗应用。对同种异体疗法的研究和基因编辑技术精确度的提高有可能简化生产并降低成本。市场的特点是快速发展，需要敏捷的策略和适应性的经营模式，以利用新趋势并有效克服现有挑战。

市场动态：快速发展的细胞和基因治疗生物製造 CDMO 市场揭示的关键市场洞察

细胞和基因疗法生物製造 CDMO 市场正在因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

• 市场驱动因素
  • 增加细胞工程、基因工程和治疗方法的研发活动
  • 治疗慢性和遗传疾病的基因疗法的需求不断增长
  • CDMO 与大公司之间的合作活动增加
• 市场限制因素
  • CDMO服务成本高
• 市场机会
  • CDMO引进数位化和人工智慧技术的倡议
  • 生物技术和製药新兴企业的增加
• 市场挑战
  • 围绕基因和细胞研究的复杂法规

波特五力：引领细胞与基因疗法生物製造 CDMO 市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对细胞和基因治疗生物製造 CDMO 市场的影响

外部宏观环境因素在塑造细胞和基因治疗生物製造 CDMO 市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞和基因治疗生物製造 CDMO 市场的竞争状况

对细胞和基因疗法生物製造 CDMO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位、基质细胞与基因治疗生物製造CDMO市场供应商绩效评估

FPNV定位矩阵是评估细胞和基因治疗生物製造CDMO市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划细胞和基因治疗生物製造 CDMO 市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，细胞和基因治疗生物製造 CDMO 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 增加细胞工程、基因工程和治疗方法的研究和开发活动
    • 对治疗慢性和遗传疾病的基因疗法的需求日益增长。
    • CDMO 和大公司之间的合作活动增加
  • 抑制因素
    • CDMO服务高成本
  • 机会
    • CDMO引进数位化和人工智慧技术的倡议
    • 生物技术和製药新兴企业的增加
  • 任务
    • 围绕基因和细胞研究的复杂法规
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章 细胞/基因治疗生物製造 CDMO 市场：依组成部分

• 细胞疗法
• 质体DNA
• 病毒载体

第七章细胞/基因治疗生物製造CDMO市场分阶段

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第八章以适应症分類的细胞/基因治疗生物製造 CDMO 市场

• 癌症
• 心血管疾病
• 遗传疾病
• 感染疾病
• 神经系统疾病

第九章北美和南美细胞/基因治疗生物製造CDMO市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十章亚太细胞与基因治疗生物製造CDMO市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十一章欧洲、中东和非洲细胞和基因治疗生物製造CDMO市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十二章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• AGC Biologics
• Almac Group
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Catalent Inc.,
• Charles River Laboratories International Inc.
• Danaher Corporation
• Endress+Hauser Group Services AG
• FUJIFILM Diosynth Biotechnologies
• GC Corporation
• General Electric Company
• Getinge AB
• Infors AG
• Lonza Group Ltd
• Merck KGaA
• Miltenyi Biotec BV & Co. KG
• Patheon Inc.
• PCI Pharma Services
• Pfizer CentreOne
• PIERRE GUERIN
• Recipharm AB
• Samsung Biologics
• Sartorius AG
• Thermo Fisher Scientific
• uBriGene
• WuXi Advanced Therapies
• WuXi AppTec

The Cell & Gene Therapy Biomanufacturing CDMO Market was valued at USD 338.12 million in 2023, expected to reach USD 485.47 million in 2024, and is projected to grow at a CAGR of 32.53%, to USD 2,428.90 million by 2030.

Cell and gene therapy biomanufacturing Contract Development and Manufacturing Organizations (CDMOs) represent a crucial segment in the biopharmaceutical industry, focusing on the bespoke production of advanced, personalized therapies targeting genetic diseases and cancers. This market segment is driven by the increasing prevalence of chronic diseases, advancements in gene editing technologies like CRISPR, and growing investments in biotech research and development. The necessity of CDMOs stems from the complex and resource-intensive nature of cell and gene therapy production, which requires specialized facilities, technical expertise, and compliance with stringent regulatory standards. Applications of these therapies are vast, spanning cancer treatment, rare genetic disorders, and regenerative medicine, with end-use primarily in hospitals, research institutes, and biotech companies. Key growth drivers include the rising approval rates of cell and gene therapies by regulatory bodies, technological advancements in manufacturing processes, and increasing public and private funding. Potential opportunities lie in expanding partnerships with biotech firms, enhancing manufacturing capabilities with automation and AI, and scaling production to meet increasing demand. Recommendations for companies include investing in state-of-the-art facilities, training a skilled workforce, and collaborating with research institutions for continuous innovation. However, market expansion is constrained by high production costs, logistical challenges in therapy delivery, and regulatory barriers. Furthermore, the high cost of therapies limits immediate patient accessibility, while ethical concerns regarding genetic modification may delay broader acceptance. Areas ripe for innovation include developing cost-effective production strategies, improving supply chain logistics, and discovering novel therapeutic applications. Research into allogeneic therapies and improving the precision of gene editing technologies could streamline production and lower costs. The market is characterized by rapid evolution, necessitating agile strategies and adaptive business models to leverage emerging trends and overcome existing challenges effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Biomanufacturing CDMO Market

The Cell & Gene Therapy Biomanufacturing CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of R&D activities in cellular and genetic engineering and therapies
  • Increasing need for genetic treatments to cure chronic and genetic disorders
  • Rising number of collaborative activities between CDMOs and major players
• Market Restraints
  • High cost of CDMO services
• Market Opportunities
  • Efforts by CDMOs to incorporate digitalization and AI technologies
  • Rising number of biotechnology and pharmaceutical startups
• Market Challenges
  • Complex regulations surrounding genetic and cell research

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Biomanufacturing CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Biomanufacturing CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Biomanufacturing CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Biomanufacturing CDMO Market

A detailed market share analysis in the Cell & Gene Therapy Biomanufacturing CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Biomanufacturing CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Biomanufacturing CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Biomanufacturing CDMO Market

A strategic analysis of the Cell & Gene Therapy Biomanufacturing CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Cell Therapy, Plasmid DNA, and Viral Vector.
• Based on Phase, market is studied across Phase 1, Phase 2, Phase 3, and Phase 4.
• Based on Indication, market is studied across Cancer, Cardiovascular Disease, Genetic Disorders, Infectious Disease, and Neurological Disorders.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
    • 5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
    • 5.1.1.3. Rising number of collaborative activities between CDMOs and major players
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of CDMO services
  • 5.1.3. Opportunities
    • 5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
    • 5.1.3.2. Rising number of biotechnology and pharmaceutical startups
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulations surrounding genetic and cell research
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component

• 6.1. Introduction
• 6.2. Cell Therapy
• 6.3. Plasmid DNA
• 6.4. Viral Vector

7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase

• 7.1. Introduction
• 7.2. Phase 1
• 7.3. Phase 2
• 7.4. Phase 3
• 7.5. Phase 4

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Cardiovascular Disease
• 8.4. Genetic Disorders
• 8.5. Infectious Disease
• 8.6. Neurological Disorders

9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AGC Biologics
• 2. Almac Group
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Bio-Techne Corporation
• 6. Catalent Inc.,
• 7. Charles River Laboratories International Inc.
• 8. Danaher Corporation
• 9. Endress+Hauser Group Services AG
• 10. FUJIFILM Diosynth Biotechnologies
• 11. GC Corporation
• 12. General Electric Company
• 13. Getinge AB
• 14. Infors AG
• 15. Lonza Group Ltd
• 16. Merck KGaA
• 17. Miltenyi Biotec B.V. & Co. KG
• 18. Patheon Inc.
• 19. PCI Pharma Services
• 20. Pfizer CentreOne
• 21. PIERRE GUERIN
• 22. Recipharm AB
• 23. Samsung Biologics
• 24. Sartorius AG
• 25. Thermo Fisher Scientific
• 26. uBriGene
• 27. WuXi Advanced Therapies
• 28. WuXi AppTec

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
• FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023